Group 1 - UBS reports that Sands China (01928) declared a final dividend of HKD 0.5 per share for the fiscal year 2025, which is in line with expectations, following an interim dividend of HKD 0.25 per share [1] - The final dividend declaration provides visibility for the fiscal year 2026, with a minimum expected dividend of HKD 1 per share (i.e., HKD 0.5 per half year), indicating potential for an increase if operating cash flow improves [1] - UBS estimates that at this level, the implied dividend yield for fiscal year 2026 is approximately 5.4%, which is attractive and should provide downside support for the stock price, with expectations of a positive market reaction [1]

Group 1 - The company, Meet Xiaomian (02408), announced a share buyback on February 16, 2026, spending HKD 950,300 to repurchase 160,500 shares [2] - The buyback price ranged from HKD 5.6 to HKD 6.0 per share [2]

该行对联想集团2026财年第三季度(2025第四季)业绩持正面看法，预期公司凭借市场领先地位、规模优 势及更高比例商用产品布局，将较少受内存成本上涨冲击。联想服务器业务亦持续扩张，盈利能力提升 主要驱动因素包括通用服务器深入更多云服务供应商布局；人工智慧服务器扩张带动产品组合升级；以 及重组措施降低成本并提升营运效率。 高盛发布研报称，将联想集团(00992)2026财年第三季业绩纳入评估，维持2027至2029财年预测基本不 变。目标价由11.98港元升至12.53港元。维持"买入"评级。 ...

美图公司(01357)发布公告，于2026年2月16日该公司斥资2001.51万港元回购321.7万股，回购价格为每 股5.99-6.31港元。 ...

新华汇富金融(00188)发布公告，于2025年11月25日至2026年2月16日期间，本公司通过其全资附属公司 于纳斯达克交易所进行一连串场内交易，进一步出售合共14.6万文远知行美国存托股份，每一文远知行 美国存托股份每日平均价格介于7.65美元至9.95美元，总代价约为127.4万美元(不含交易成本)。 ...

国际家居零售(01373)发布公告，于2026年2月16日该公司斥资11.1万港元回购15万股，回购价格为每股 0.74港元。 ...

消息面上，业务利好加持。近日，医渡科技与华中科技大学同济医学院附属同济医院(下称"同济医院") 联合申报的胃肠肿瘤诊疗多模态AI数据库项目成功入选国家工信部2025年人工智能医疗器械创新任 务"揭榜挂帅"名单。此外，医渡科技的发展前景也获得机构的认可。2月花旗发布研报维持医渡科技"买 入"评级，并将其目标价上调至11港元。 回顾2026年以来的回购历程，医渡科技的回购呈现"高频次、稳力度"的显著特征。自1月26日开启本年 度首次回购以来，公司仅用不到一个月时间便完成15次回购，回购节奏连贯且坚定。 2026年以来，港股市场的回购热潮仍在持续，其中龙头企业依旧扮演着回购"主力军"的角色，持续通过 回购动作传递对公司内在价值的认可与未来发展的信心，医渡科技(02158)便是AI医疗领域的典型代 表。 2月16日，医渡科技再度发布股份回购公告：公司当日以每股约5.91港元的价格回购40.4万股，耗资将近 240万港元，这也是其2026年以来实施的第15次回购，延续了自1月26日以来的密集回购节奏，累计已耗 资接近6700万港元。 ...

Group 1 - The company Prudential (02378) announced a share buyback plan, committing to repurchase 612,500 shares at a total cost of £6.4983 million [1] - The buyback price per share is set between £10.37 and £10.87 [1]

Core Viewpoint - Hua Hong Semiconductor's performance in Q4 last year and guidance for Q1 this year are generally in line with expectations, with growth in AI-related products offsetting declines in consumer electronics due to memory shortages [1] Group 1: Financial Performance - Hua Hong's Q4 performance and Q1 guidance are largely as anticipated, indicating stability in operations [1] - The company expects continued rapid growth in AI-related products such as power management ICs and microcontrollers (MCUs) [1] Group 2: Capacity and Investment - The new 12-inch wafer fab, Fab9A, is projected to reach maximum capacity this year, while the capacity enhancement of Fab9B will accelerate [1] - Capital expenditures are expected to slightly decrease in 2026 but will significantly increase in 2027 [1] Group 3: Analyst Ratings - Citi has raised its target price for Hua Hong to HKD 129.5 and reiterated a "outperform" rating [1]

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月16日该公司斥资238.9万港元回购40.4万股， 回购价格为每股5.77-6.00港元。 ...